Untitled Document
[an error occurred while processing this directive]
1-15 March 2009  
Untitled Document

Go Gujarat Spl.
Pharma Life

Editorial Advisory Board
Open Forum
Media Kit
Contact Us
Network Sites
Express Computer
Express Channel Business
Express Hospitality
Express TravelWorld
Express Healthcare
Group Sites
Indian Express
Financial Express

[an error occurred while processing this directive]

[an error occurred while processing this directive]

[an error occurred while processing this directive]
Home - Market - Article

Company Watch

Wockhardt introduces Glaritus in India

Our News Bureau - Mumbai

Pharmaceutical and biotechnology company Wockhardt has launched its new insulin (Glaritus), a recombinant long acting human insulin analogue. The product is the biosimilar of a glargine insulin marketed by Sanofi-Aventis under the brand name Lantus, Currently, the worldwide market of glargine insulin is $2 billion. As per ORG IMS estimates, the current market for insulin analogues in India is Rs 120 crore and it is growing at 37 percent per annum.

Glaritus has been clinically tested on 300 diabetic patients for safety and efficacy parameters and is approved by the Drug Controller General, (India) (DCGI). As per a company press release, Wockhardt is the first company in the world after the innovator (Sanofi-Aventis) to launch an insulin analogue that works slowly over a 24 hour period. Glaritus is manufactured at Wockhardt's state-of-the-art biotech park in Aurangabad. It is available to patients as reusable and disposable pen delivery devices.

"Back in 2003, when I promised that we would launch Glaritus, the world's most advanced insulin, there was disbelief all around. Today, the world will look at India in admiration. The nation's biotech prowess would once again be a global talking point," said Wockhardt Chairman Habil Khorakiwala.

The launch of Glaritus is a significant landmark for India, which has one of the highest diabetes affected populations in the world. The advantage of Glaritus is that it is a once daily dose and provides basal glucose control over 24 hours. Glaritus can hence be easily combined with other oral medications of diabetes for effective blood glucose control. Moreover, Glaritus is a meal independent, peak less insulin, which reduces incidences of hypoglycaemia significantly. All this translates into more compliance to insulin therapy, improved blood glucose control and therefore slower progression of diabetes related complications.

"Wockhardt becomes the first company in the biotechnology space to move from simple biologicals to complex biologicals with vast experience in both, E.coli and Yeast platforms," he further added. Wockhardt has built a comprehensive diabetes management portfolio that includes insulins, oral medications, blood glucose monitors and diabetes nutrition products.


Untitled Document
Copyright 2001: The Indian Express Limited. All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of The Indian Express Limited. Site managed by BPD.